194 related articles for article (PubMed ID: 15800717)
1. The influence of thalidomide therapy on cytokine secretion, immunophenotype, BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma.
Dmoszynska A; Podhorecka M; Manko J; Bojarska-Junak A; Rolinski J; Skomra D
Neoplasma; 2005; 52(2):175-81. PubMed ID: 15800717
[TBL] [Abstract][Full Text] [Related]
2. Influence of thalidomide on Bcl2 expression and proangiogenic cytokine levels in short-term culture of peripheral blood and bone marrow mononuclear cells of multiple myeloma patients.
Dmoszyńska A; Roliński J; Bojarska-Junak A; Mańko J; Jawniak D; Walter-Croneck A; Soroka-Wojtaszko M; Hus M
Pol J Pharmacol; 2001; 53(6):709-13. PubMed ID: 11985351
[TBL] [Abstract][Full Text] [Related]
3. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.
Cibeira MT; Rozman M; Segarra M; Lozano E; Rosiñol L; Cid MC; Filella X; Bladé J
Cytokine; 2008 Mar; 41(3):244-53. PubMed ID: 18178097
[TBL] [Abstract][Full Text] [Related]
5. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
[TBL] [Abstract][Full Text] [Related]
6. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma.
Neben K; Moehler T; Egerer G; Kraemer A; Hillengass J; Benner A; Ho AD; Goldschmidt H
Clin Cancer Res; 2001 Sep; 7(9):2675-81. PubMed ID: 11555579
[TBL] [Abstract][Full Text] [Related]
7. [Influence of thalidomide on bone marrow microenvironment in refractory and relapsed multiple myeloma].
Li J; Luo SK; Hong WD; Zhou ZH; Zou WY
Ai Zheng; 2003 Apr; 22(4):346-9. PubMed ID: 12703985
[TBL] [Abstract][Full Text] [Related]
8. Influence of lovastatin on BCL-2 and BAX expression by plasma cells and T lymphocytes in short-term cultures of multiple myeloma bone marrow mononuclear cells.
Dmoszyńska A; Podhorecka M; Roliński J; Soroka-Wojtaszko M
Pol J Pharmacol; 2004; 56(4):485-9. PubMed ID: 15520505
[TBL] [Abstract][Full Text] [Related]
9. Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma.
Dmoszyńska A; Bojarska-Junak A; Domański D; Roliński J; Hus M; Soroka-Wojtaszko M
Leuk Lymphoma; 2002 Feb; 43(2):401-6. PubMed ID: 11999576
[TBL] [Abstract][Full Text] [Related]
10. [The efficacy of thalidomide for multiple myeloma: a clinical analysis of 102 Chinese patients].
Qi PJ; Wang YF; Xu Y; Li YN; Zou DH; Zhao YZ; Xiao ZJ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):226-9. PubMed ID: 18843974
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma.
Herth I; Witzens-Harig M; Beckhove P; Hose D; Meissner T; Neuber B; Engelhardt M; Haas J; Neben K; Ho AD; Klein B; Goldschmidt H; Hundemer M
Exp Hematol; 2013 Mar; 41(3):231-40. PubMed ID: 23142220
[TBL] [Abstract][Full Text] [Related]
12. Antigen-specific T-cell immunity in multiple myeloma patients is restored following high-dose therapy: implications for timing of vaccination.
Svane IM; Nikolajsen K; Johnsen HE
Scand J Immunol; 2007 Oct; 66(4):465-75. PubMed ID: 17850592
[TBL] [Abstract][Full Text] [Related]
13. [Influence of thalidomide on interleukin-6 and its transmission in multiple myeloma patients].
Li J; Luo S; Hong W; Zhou Z; Zou W
Zhonghua Zhong Liu Za Zhi; 2002 May; 24(3):254-6. PubMed ID: 12515619
[TBL] [Abstract][Full Text] [Related]
14. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma.
Neben K; Moehler T; Benner A; Kraemer A; Egerer G; Ho AD; Goldschmidt H
Clin Cancer Res; 2002 Nov; 8(11):3377-82. PubMed ID: 12429624
[TBL] [Abstract][Full Text] [Related]
15. Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vbeta repertoire.
Pérez-Andres M; Almeida J; Martin-Ayuso M; Moro MJ; Martin-Nuñez G; Galende J; Hernandez J; Mateo G; San Miguel JF; Orfao A; ;
Cancer; 2006 Mar; 106(6):1296-305. PubMed ID: 16475149
[TBL] [Abstract][Full Text] [Related]
16. Etodolac induces apoptosis and inhibits cell adhesion to bone marrow stromal cells in human myeloma cells.
Nakamura S; Kobayashi M; Shibata K; Sahara N; Shigeno K; Shinjo K; Naito K; Hayashi H; Ohnishi K
Leuk Res; 2006 Feb; 30(2):123-35. PubMed ID: 16046235
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
[TBL] [Abstract][Full Text] [Related]
18. [Thalidomide therapy in patients with refractory or relapsed multiple myeloma].
Ochiai N; Shimazaki C; Uchida R; Fuchida S; Okano A; Ashihara E; Inaba T; Fujita N; Adachi Y; Nishio A; Nakagawa M
Rinsho Ketsueki; 2002 Dec; 43(12):1045-9. PubMed ID: 12607993
[TBL] [Abstract][Full Text] [Related]
19. Relationship between CD38 expression on peripheral blood T-cells and monocytes, and response to antiretroviral therapy: a one-year longitudinal study of a cohort of chronically infected ART-naive HIV-1+ patients.
Almeida M; Cordero M; Almeida J; Orfao A
Cytometry B Clin Cytom; 2007 Jan; 72(1):22-33. PubMed ID: 17051525
[TBL] [Abstract][Full Text] [Related]
20. Response to thalidomide in multiple myeloma: impact of angiogenic factors.
Rosiñol L; Cibeira MT; Segarra M; Cid MC; Filella X; Aymerich M; Rozman M; Arenillas L; Esteve J; Bladé J; Montserrat E
Cytokine; 2004 May; 26(4):145-8. PubMed ID: 15149630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
